Pfizer Needs Big Earnings Beat

NEW YORK ( TheStreet) -- Falling earnings don't make for a strong stock; however, Pfizer's (PFE) shares have continued to move higher.

Who They Are: Pfizer is a research-based, global pharmaceutical company that trades an average of 56.4 million shares per day with a marketcap of $175 billion.

Pfizer is forecast to record lackluster second-quarter earnings before the market opens on July 31. The consensus estimate is currently 55 cents a share, a fall of 5 cents (8.3%) from 60 cents during the equivalent quarter last year.

Fifteen out of 17 analysts covering the stock (over 70%) rate Pfizer a buy or strong buy. The company has two holds, and not one sell rating. The stock has appreciated 19.1% in the last year, and the average analyst target price for PFE is $25.58.

May 1 was the last earnings release with a closing price of $22.78, compared to a current price of $23.33. (Read a recent bullish article including Pfizer Are Elan, Pfizer, Lilly and J&J Buys After a Failed Drug Test? )

Management is executing with an increase of year-over-year revenue. Revenue reported was $67.43 billion last fiscal year compared to $67.06 billion in the previous year. The bottom line has rising earnings year-over-year of $10.01 billion last fiscal year compared to $8.26 billion in the previous year.

PFE beat earnings in all four of the last four quarters, with an average beat of 3 cents (5.56%) per share.

PFE PE Ratio Chart PFE PE Ratio data by YCharts

Industry and peer comparisons of companies that report before Pfizer:

Johnson & Johnson ( JNJ) recently beat earnings by a penny with $1.30 EPS. Wall Street wasn't pleased and shares have fallen about $2 a share to trade near $67.50.

Analysts as a whole like this company. Currently, J&J has 15 buy recommendations out of 23 analysts covering the company, eight holds and zero sell ratings. Over half the analysts covering J&J rate it as a buy or a strong buy.

J&J has appreciated 2.2% in the last year, and the average analyst target price for J&J is $74.60. J&J has a sizeable short interest of 9.5%.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux